The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

901694899688899175031c716e-85d6-489d-a2f6-78221947b25f4fd4a0fd-37be-408b-81e5-604bed3904583fa1a147-e1cb-4a64-858b-4ad8d98b53e9ARGS_News_2016_7_27_General_Releases.pdfARGS_News_2016_7_14_General_Releases.pdfARGS_News_2016_7_11_General_Releases.pdf1163213084125741232016-7-27T16:6:11-4:02016-7-14T8:30:0-4:02016-7-11T8:0:0-4:0981500979564978849General ReleasesGeneral ReleasesGeneral ReleasesArgos Therapeutics Announces Proposed Public Offering of Common Stock and WarrantsArgos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIVDr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer142142142201620162016No Error0

Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Read more

Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
Read more

Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC